Akkermansia muciniphila​ (AKK), often referred to as the “longevity probiotic,” has garnered increasing attention for its promising role in promoting healthy aging.

Chronic kidney disease (CKD) is a significant health problem that affects millions of individuals globally. The need for effective therapeutic agents has led to the exploration of probiotics as a potential treatment. This journal focuses on a specific probiotic agent designed to improve CKD, its composition, and its applications, as described in the patent.

This patent delves into the detailed examination of the Akkermansia muciniphila Akk007, a probiotic with significant immunomodulatory properties.

Recent groundbreaking research published in Nature Microbiology has highlighted the significant role of Akkermansia muciniphila (Akk) in combating metabolic disorders.

In the world of probiotics, Akkermansia muciniphila is emerging as a revolutionary player with promising potential for enhancing gut health and aiding in weight management.

The patent describes the discovery and application of a specific strain of Limosilactobacillus reuteri (LR38), preserved under CGMCC No.24408, which is effective in improving polycystic ovary syndrome (PCOS).